What question did this study set out to answer?

To evaluate the safety, cardiotoxicity, and antitumor efficacy of liposome-encapsulated doxorubicin (Myocet) versus conventional doxorubicin when combined with cyclophosphamide as first-line therapy for metastatic breast cancer.

March 1, 2001Journal of Clinical Oncology

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

View Full Paper

Ask AI

Bookmark

Why the study?

Does liposome-encapsulated doxorubicin combined with cyclophosphamide reduce cardiotoxicity and preserve antitumor efficacy compared to conventional doxorubicin and cyclophosphamide in patients with metastatic breast cancer?

Population

Patients with metastatic breast cancer (MBC) receiving first-line therapy

Comparison

Liposome-encapsulated doxorubicin in combination… vs Conventional doxorubicin and cyclophosphamide

Design

RCT, Randomized

Authors

GBGerald BatistJewish General Hospital GRGopal RamakrishnanFortis Healthcare CRChandra Sekhar RaoGujarat Cancer & Research Institute

Discussion

Member takes

Implication

Supports liposomal doxorubicin plus cyclophosphamide as first-line option in metastatic breast cancer; confirms reduced cardiotoxicity with preserved efficacy in RCT.

Key Points

To evaluate the safety, cardiotoxicity, and antitumor efficacy of liposome-encapsulated doxorubicin (Myocet) versus conventional doxorubicin when combined with cyclophosphamide as first-line therapy for metastatic breast cancer.
Conducted a randomized, multicenter clinical trial in patients receiving first-line chemotherapy for metastatic breast cancer.
Assigned patients to receive either liposome-encapsulated doxorubicin (Myocet) plus cyclophosphamide or conventional doxorubicin plus cyclophosphamide.
Liposomal doxorubicin significantly reduced the incidence of cardiotoxicity and grade 4 neutropenia compared with conventional doxorubicin.
Antitumor efficacy was comparable between the two regimens, resulting in an improved overall therapeutic index for liposomal doxorubicin.

Structured PICO

Population

Patients with metastatic breast cancer (MBC) receiving first-line therapy

Intervention

Liposome-encapsulated doxorubicin in combination with cyclophosphamide

Comparator

Conventional doxorubicin and cyclophosphamide

Outcome

Cardiotoxicity, grade 4 neutropenia, and antitumor efficacysafety

Liposome-encapsulated doxorubicin combined with cyclophosphamide offers a safer alternative to conventional doxorubicin for first-line metastatic breast cancer treatment by reducing cardiotoxicity without compromising efficacy.

Cite This Study

Batist et al. (2001) studied this question.

synapsesocial.com/papers/69d5708675589c71d767dcdd https://doi.org/10.1200/jco.2001.19.5.1444

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Implication

Supports liposomal doxorubicin plus cyclophosphamide as first-line option in metastatic breast cancer; confirms reduced cardiotoxicity with preserved efficacy in RCT.

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider